Larson Financial Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.2K Sell
411
-208
-34% -$14.2K ﹤0.01% 1743
2026
Q1
$40K Buy
619
+345
+126% +$24.3K ﹤0.01% 1465
2025
Q4
$18.4K Sell
274
-80
-23% -$5.38K ﹤0.01% 1768
2025
Q3
$26K Buy
354
+343
+3,118% +$22.8K ﹤0.01% 1489
2025
Q2
$572 Buy
11
+4
+57% +$228 ﹤0.01% 2824
2025
Q1
$447 Buy
7
+5
+250% +$290 ﹤0.01% 2606
2024
Q4
$96 Sell
2
-192
-99% -$9.85K ﹤0.01% 2608
2024
Q3
$11.1K Buy
194
+192
+9,600% +$11K ﹤0.01% 1441
2024
Q2
$105 Hold
2
﹤0.01% 2231
2024
Q1
$81 Hold
2
﹤0.01% 1720
2023
Q4
$74 Buy
+2
New +$75 ﹤0.01% 1732

Other funds holding HALO

Larson Financial Group's HALO Position: Q2 2026 in Review

Larson Financial Group reduced its Halozyme (HALO) stake by 34% in Q2 2026, selling an estimated $14.2K and leaving 411 shares worth $32.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Larson Financial Group first reported a position in HALO in Q4 2023 and has held it in 11 quarters since. The position peaked at $40K in Q1 2026. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Larson Financial Group held 411 shares of Halozyme worth $32.2K as of Q2 2026.
  • Larson Financial Group sold 208 Halozyme shares in Q2 2026, an estimated $14.2K.
  • Halozyme made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #1743 holding.
  • Larson Financial Group first reported a position in Halozyme in Q4 2023 and has held it in 11 quarters since.
  • Larson Financial Group's Halozyme position peaked at $40K in Q1 2026.
  • 672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.